FY2027 EPS Estimates for Envista Lifted by Leerink Partnrs

Envista Holdings Co. (NYSE:NVST) – Analysts at Leerink Partnrs lifted their FY2027 earnings per share (EPS) estimates for Envista in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $1.45 per share for the year, up from their prior forecast of $1.41. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Envista’s current full-year earnings is $1.06 per share.

Several other research firms have also weighed in on NVST. Wells Fargo & Company upped their price objective on shares of Envista from $20.00 to $21.00 and gave the company an “equal weight” rating in a research note on Thursday, February 6th. Robert W. Baird increased their price objective on Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, October 31st. Piper Sandler lifted their price objective on Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Jefferies Financial Group upped their target price on Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Finally, Mizuho assumed coverage on Envista in a report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price target for the company. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Envista has a consensus rating of “Hold” and a consensus target price of $20.21.

Envista Stock Down 0.0 %

Shares of NYSE:NVST opened at $21.24 on Monday. The firm has a 50 day simple moving average of $19.94 and a 200 day simple moving average of $19.20. Envista has a 52 week low of $15.15 and a 52 week high of $23.06. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.77 and a current ratio of 2.04. The company has a market cap of $3.66 billion, a PE ratio of -3.27, a price-to-earnings-growth ratio of 2.06 and a beta of 1.34.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%.

Institutional Investors Weigh In On Envista

A number of hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Envista in the third quarter worth $31,000. GAMMA Investing LLC grew its position in Envista by 69.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after purchasing an additional 726 shares during the last quarter. Huntington National Bank increased its holdings in shares of Envista by 97.8% during the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after purchasing an additional 949 shares during the period. Venturi Wealth Management LLC raised its position in shares of Envista by 528.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock valued at $38,000 after buying an additional 1,638 shares during the last quarter. Finally, Blue Trust Inc. lifted its stake in shares of Envista by 69.7% in the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after buying an additional 804 shares during the period.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.